Joseph, D., Thoma, C., Haeufel, T., & Li, X. (2022). Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies. Clinical pharmacokinetics, 61(12), 1771-1787. https://doi.org/10.1007/s40262-022-01176-5
Citácia podle Chicago (17th ed.)Joseph, David, Christian Thoma, Thomas Haeufel, a Xiujiang Li. "Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies." Clinical Pharmacokinetics 61, no. 12 (2022): 1771-1787. https://doi.org/10.1007/s40262-022-01176-5.
Citácia podľa MLA (8th ed.)Joseph, David, et al. "Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies." Clinical Pharmacokinetics, vol. 61, no. 12, 2022, pp. 1771-1787, https://doi.org/10.1007/s40262-022-01176-5.